In vivo regulation of central nervous system progesterone receptors: cocaine induces steroid-dependent behavior through dopamine transporter modulation of D5 receptors in rats.

To characterize the membrane pathway by which the cocaine-sensitive dopamine transporter (DAT) modulates progesterone receptor activation, steroid-dependent behavior lordosis was used in estrogen-primed ovariectomized Sprague-Dawley rats with stereotaxic implanted third ventricle cannulas. Lordosis in response to solicitous males was observed in females after intercerebral ventricular administration of DAT antagonists WIN35,428 (80 ng) and cocaine (0.016-1.6 micrograms). Significantly, antisense oligonucleotides (AS) to DAT mRNA also induced reproductive behavior. In contrast, the D1-D2 receptor membrane-repopulation inhibitor N-ethoxycarbonyl-2 ethoxy-1,2-dihydroquinoline and the D1-like antagonist SCH23390 blocked cocaine-inducible behavior. Further, facilitation of behavior by AS to the DAT was suppressed by N-ethoxycarbonyl-2 ethoxy-1,2-dihydroquinoline. Behavior was not dependent on D2 receptors, since animals pretreated with the D2 antagonist sulpride displayed lordosis after cocaine challenge. Antisense oligonucleotides to D5 but not D1 dopamine receptor mRNA suppressed reproductive behavior associated with cocaine. Microinjections of cocaine to the ventromedial nucleus (VMN) but not arcuate nucleus or preoptic area potentiated lordosis, suggesting the functional presence of DAT in the VMN. Finally, cocaine facilitation of behavior was blocked by both antiprogestin RU486 and progesterone receptor AS microinjected into either the third ventricle or the VMN. Collectively, the data provide strong evidence for cocaine modulation of reproductive behavior through presynaptic cocaine-sensitive dopamine transporters and postsynaptic D5 dopamine receptor mediation of progesterone receptor-dependent behavior in rat central nervous system.

Epidermal growth factor activates reproductive behavior independent of ovarian steroids in female rodents.

Sex steroids exert profound influence on neural development and function through activation of intranuclear receptors. However, during sexual differentiation and at onset of puberty, intracerebral estrogen (E) availability is subsequent to these effects. The potent mitogen epidermal growth factor (EGF) activates estrogen receptor (ER)-dependent transcription in cultured cells in the absence of exogenous E. Since reproductive behavior in female rodents is the result of E-dependent transcriptional activity and protein synthesis, lordosis serves as a well established in vivo model for probing cellular and molecular mechanisms of steroid receptor-dependent behavior. Here we demonstrate that EGF can signal through the classical E receptor (ERalpha) to alter in vivo function in rodent central nervous system. EGF and EGF receptor ligands induced lordosis in a dose- and time-dependent manner in the absence of steroid treatment in ovariectomized rats and mice. Using antisense oligonucleotides, pharmacological and antibody blockade, and mutant mice, we also report that this behavioral responsiveness is mediated through ERalpha by specific stimulation of membrane-bound EGF receptors and EGF receptor-specific tyrosine kinase rather than by direct ligand activation of the ERalpha. Of biological significance, delayed onset of puberty and the absence of synchronization between reproductive behavior and ovulation was detected in intact mutant Wa-2 mice that express a naturally occurring point mutation in the EGF receptor. To our surprise, EGF-mediated behavior was independent of progesterone (P) and progesterone receptor (PR) since antiprogestins, PR antisense oligonucleotides, and targeted disruption of PR in ovariectomized transgenic mice failed to impede the display of lordosis after EGF. Finally, we also found that another growth factor, insulin-like growth factor-1, which provokes ER-dependent transcription in vitro, activates mating behavior in a similar E-independent manner. Thus, growth factor mediation of ER-targeted function may be a universal feature in the rodent central nervous system, raising critical questions about the role of growth factors in mediating ER-dependent processes in development and reproduction.

Estrogen affinity crosslinking to tyrosinase-like immunoreactive proteins of rat uterine nuclear extracts.

We have previously described tyrosinase-like proteins of rat uterine nuclear extracts with type II estrogen binding characteristics. In this paper we have been able to affinity label these polypeptides with radio-iodinated estradiol. The major label at approximately 33-38 kDa comigrates with a approximately 36 kDa tyrosinase immunoreactive band assessed by autoradiograms and Western blots following electrophoresis. A minor label was also detected at approximately 45 kDa. The label is attenuated by excess quercetin hence these proteins are believed to represent putative type II estrogen binding sites that bind this bioflavonoid. These estrogen binding proteins are distinct from the estrogen receptor as judged by immunoblotting. The affinity crosslinking will be a useful approach in the purification of tyrosinase like proteins.

Tyrosinase-like activity and estradiol binding in rat uterine nuclear extracts.

Nuclear extracts from the uteri of estradiol-implanted rats contain a tyrosinase-like enzyme that has three activities: monophenolase or cresolase, diphenolase or catecholase, and estrogen binding. When [3H]estradiol was used as a substrate, 3H2O was released from the A ring in the presence of copper and ascorbic acid. The optimal concentrations of these cofactors for the cresolase activity were established. The cresolase activity was lost on attempts at further purification. Estradiol binding was observed in conjunction with the enzymatic activity and was dependent on the presence of ascorbic acid and copper. The most potent inhibitors of 3H2O release from [3H]estradiol were those with a dihydroxyphenol moiety. The reaction was also sensitive to sulfhydryl reagents. These features of the enzyme are distinctive from other oxidases capable of attacking the aromatic ring of estrogens.

Tyrosinase-like polypeptides in the uterus and in the central nervous system of rats.

Nuclear and cytosolic fractions of rat uteri and tissues from the central nervous system contain proteins that are recognized by a polyclonal tyrosinase antibody. This antibody eliminates the cresolase activity of uterine nuclear extract when estradiol is used as substrate. Thus, it appears that tyrosinase-like proteins might be present in tissues not generally considered to chain such an enzyme.

Hepatic dysfunction in development of menopausal hot flushes?

Obese menopausal women tend to suffer more frequently and more severely from hot flushes, though they have higher residual estrogen levels due to the conversion of adrenal androgens in fat tissue. Phytoestrogens, while not exhibiting clinically relevant estrogenic effects on peripheral reproductive tissues, seem to alleviate hot flushes in doses attainable with dietary supplementation. This paper aims to address these controversies. A synergistic action of obesity and estrogens may cause hepatic dysfunction involving inflammatory Kupffer cell activation and generation of pyrogenic signals that reach the thermoregulatory centers via the vagal route. Sudden withdrawal of this perpetual pyrogenic impetus at the onset of menopause results in a thermoregulatory imbalance. The occasional downward sliding of the thermoregulatory setpoint serves to trigger the hot flush event. Repercussions of this theory involve a possible resolution for the paradox of why estrogen-sensitive cancers manifest more frequently at the age when endogenous estrogen levels decline.

Hormonal action of plant derived and anthropogenic non-steroidal estrogenic compounds: phytoestrogens and xenoestrogens.

Herbivorous and omnivorous vertebrates have evolved in the presence of a variety of phytoestrogens, i.e., plant-derived compounds that can mimic, modulate or disrupt the actions of endogenous estrogens. Since the discovery of the estrus-inducing effects of some plant products in 1926, considerable effort has been devoted to the isolation and structural and pharmacological characterization of phytoestrogens. Recently, agricultural and industrial pollution has added anthropogenic estrogenic compounds to the list of environmental estrogens. Unlike phytoestrogens, these xenoestrogens tend to accumulate and persist in adipose tissue for decades and may cause long-lasting, adverse endocrine effects. Here we review the endocrine effects of known phytoestrogens and xenoestrogens with special emphasis on molecular structure-activity relationships. Phytoestrogens include flavonoids, isoflavonoids, chalcons, coumestans, stilbenes, lignans, ginsenosides and other saponins, as well as the recently discovered tetrahydrofurandiols. Fungal estrogenic compounds may enter the food chain via infested crops. Since some phytoestrogens have been shown to display organ-specific actions, pharmaceutical estrogen analogues with similar properties (selective estrogen receptor modulators, SERMs) are also discussed. Xenoestrogens include dichlorodiphenyltrichloroethane (DDT) and its metabolites, bisphenols, alkylphenols, dichlorophenols, methoxychlor, chlordecone, polychlorinated benzol derivatives (PCBs), and dioxins. While most of these compounds act through estrogen receptors alpha and beta, some of their effects may be mediated by other nuclear or membrane-bound receptors or receptor-independent mechanisms. Some might also interfere with the production and metabolism of ovarian estrogens. Better understanding of the molecular pharmacology of phyto- and xenoestrogens may result in the development of novel compounds with therapeutic utility and improved environmental protection.

Pelvic pain in endometriosis: painkillers or sport to alleviate symptoms?

To assess potential individual factors influencing quality of life and pain scores of patients suffering from histologically confirmed endometriosis. Study using a questionnaire among patients of reproductive age undergoing laparoscopy with a presumed diagnosis of endometriosis. Details of fertility, previous treatments and quality of life, sexual activity, as well as linear pain scores for several symptoms, were recorded. Details of intraoperative findings were also collected and only those data were used where endometriosis was intraoperatively and histologically proven. A questionnaire before surgery gathered information from women on the following groups of variables: age, marital status, education, reproductive and medical history including previous pregnancies and parity, knowledge of accompanying pelvic disorders, regular sport activity, as well as general quality of life estimates including self-image. Pelvic pain was scored using a visual analogue scale. Data were statistically evaluated. Eighty-one patients complaining about persistent pelvic pain were later intraoperatively and histologically proven to have endometriosis. Thirty-one of them (38.2%) reported regular sport as part of their daily life schedule while 50 of them (61.8%) performed no physical activity at all. Fourteen patients among regular exercisers and 33 patients among those without physical activity reported the effectiveness of painkillers for pelvic pain, corresponding to 45.1% and 66% of these subgroups, respectively (difference statistically significant, p<0.05). Based on our results, we can conclude, that taking painkillers might be less effective among endometriosis patients performing regular daily sport activities, and, thus it might impose them to an unnecessary burden of possible side-effects.

Low dose RU486 prevents progesterone antagonism on uterine growth and concomitant type II oestradiol binding induction by oestradiol in rats.

The effect of RU486, a synthetic antisteroid, on the antagonism of progesterone (Pg) and dexamethasone (Dex) against oestradiol (Oe) induced uterine growth, and on uterine oestradiol binding (type I and type II sites) was studied in ovariectomized CFY rats. Changes of hypothalamic low affinity [3H]Oe binding have also been evaluated. Inhibitory effects of Pg but not of Dex on uterine growth and type II Oe binding site induction were prevented by RU486. Antiprogestin effect of RU486 could also be demonstrated on low affinity [3H]Oe binding in hypothalami. The inhibitory effect of dexamethasone on type II Oe binding was not opposed by antisteroid, on the contrary, RU486 seemed to potentiate this effect of Dex. Evaluation of type I binding was complicated by the distorting effect of type II binding at the saturation curve. Changes of type I binding seemed to parallel those of type II binding except after Oe+Dex treatment where an increased level of uterine cytoplasmic type I sites and a simultaneous decrease of type II sites were found. Blockage of [3H]Oe binding at high RU486 concentrations was found in vitro in the uterine cytoplasmic fraction. A less pronounced effect was observed in the nuclear fraction. Possible mechanisms of the RU486 effect on type II Oe binding are discussed.

On the mechanism of opioid-oestradiol interactions.

Characteristics of opioid binding and possible relationships between oestradiol and opioid binding sites were studied in rat oestrogen sensitive tissues(uterus, preoptic area-anterior hypothalamus, median eminence-basal hypothalamus). Naloxone (Nal) and oestradiol (Oe) bindings were assessed by in vitro saturation analyses. In 800 g supernatants of both uterine and hypothalamic tissues homogenates high affinity (Kd: 2-4 X 10(-9) M) and low capacity [3H]Nal binding sites were found. These binding sites were sedimented from 800 g supernatant by further centrifugation at 10(5) g for 1 h. In competition studies [3H]Nal binding was completely prevented by morphine, while met-enkephalin and leu-enkephalin caused only a partial inhibition. [3H]Nal binding was increased by ovariectomy and decreased by Oe treatment (10 micrograms/100 g b.wt) in both tissues. The cytoplasmic [3H]Oe binding in the studied tissues seems to be affected by the naloxone binding system. After in vitro saturation of naloxone binding sites by naloxone the [3H]Oe binding to low affinity sites (type II) in hypothalamus as well as in uterus has been increased by 8- and 2-fold, respectively. These results indicate the presence of specific [3H]Nal binding in rat uterus with similar properties to those found in the hypothalamus. Furthermore an interaction between opioid and oestradiol receptor systems could be also suggested.

In vitro effects of cytosolic inhibitor and opiates on the binding of [3H]oestradiol to nuclear type II binding sites of rat uterus and hypothalamus.

The effect of cytosolic ultrafiltrates prepared from intact rat uteri, brain hemispheres and hypothalami and of some opiate analogues on oestradiol binding to nuclear type II sites in rat uterus and hypothalamus was studied. Opiate binding in nuclear fraction of rat uteri was also evaluated. Both uterine and hypothalamic low affinity nuclear oestradiol binding was inhibited by filtrate from uteri, while only hypothalamic nuclear binding was decreased in presence of hypothalamic filtrate. Filtrate from brain was ineffective on nuclear oestradiol binding of the studied tissues. Concentration dependent inhibition of uterine nuclear oestradiol binding could be demonstrated by some opiate analogues in vitro. Specific low affinity nuclear binding of opiate antagonist naloxone and agonist dihydromorphine was observed in rat uteri which could be inhibited by uterine filtrate and oestradiol but not by hypothalamic filtrate or other steroids. Present findings support the probable intracellular interplay of opiates and oestradiol action and suggest that cytosolic inhibitor factor might be involved.

Charcoal stripping augments type II oestradiol binding in cytoplasmic fraction of rat hypothalami.

Type II [3H]oestradiol binding was assessed by charcoal method in the low speed cytoplasmic fraction of intact female rat hypothalami. Augmented binding was observed after charcoal pretreatment applied prior to binding assay. On the other hand, loss of low affinity oestradiol binding was demonstrated after addition of protein-free ultrafiltrates of the cytosol from hypothalami or uteri. The presence of a cytosolic inhibitor activity specific for type II oestradiol binding in hypothalami is considered.

Issues to debate on the Women's Health Initiative: estrogen: an instrument or the conductor of the orchestra?

Although it is well known that cyclic production of sex hormones is essential to establish reproductive function and female characteristics, distant impacts of the activity of the female endocrine system result from a concert of delicate mechanisms. Estrogen is rather an instrument than a conductor in this physiological orchestra of the female. Thus, controversies in the explanation of results from studies on hormone replacement therapy (HRT) and cardiovascular disease (CVD) prevention might be eliminated, if we analyse not only the role of estrogen but a broader spectrum of factors leading to CVD. Authors would like to hypothesize that haemorheological changes in women around menopause, such as increased blood and plasma viscosity, haematocrit and fibrinogen, are largely responsible for the increased mortality in the post-menopausal life period. We believe that a cyclic withdrawal bleeding establishes a more favourable haemorheological condition, thus, sequentially administered estrogen might be protective in post-menopausal women. Nevertheless, other factors, that decrease blood viscosity, such as daily exercise, intake of ample amount of fluids as well as ideal nutrition, are equally important. We are confident that sequential HRT, as well as healthy life style and risk prevention programmes have their proper place in the management of this issue.

Dopaminergic regulation of progesterone receptors: brain D5 dopamine receptors mediate induction of lordosis by D1-like agonists in rats.

To characterize the signaling pathway by which the neurotransmitter dopamine modulates progesterone receptor (PR) activation, the steroid-dependent behavior lordosis was used in estrogen-primed ovariectomized Sprague-Dawley rats with stereotaxic implanted third ventricle cannulas. Lordosis was observed in response to solicitous males in females after central administration of the D1-like agonist SKF38393 and three of its analogs (SKF77434, SKF75640, and SKF85174). In contrast, D1-like antagonist SCH23390 and D1-like/D2 repopulation inhibitor EEDQ blocked behavior inducible by the D1-like agonists. Further, antisense oligonucleotides to D5, but not D1, dopamine receptor mRNA suppressed reproductive behavior associated with D1-like stimulation. This finding provides strong evidence that dopaminergic modulation of lordosis is mediated by the novel D5 dopamine receptor. Although D1, but not D5, dopamine receptor mRNAs were detected in the ventromedial nucleus (VMN) by in situ hybridization, agonists microinjected into the VMN, but not into the arcuate nucleus or preoptic area, induced lordosis, suggesting the functional presence of D5 dopamine receptors in the VMN. Also in support, D5 receptor mRNA antisense microinjected into the VMN blocked the subsequent induction of lordosis by D1-like agonists. Finally, facilitation of sex behavior by D1-like agonists was blocked by the antiprogestin RU38486 and PR antisense oligonucleotide. Collectively, the data provide strong evidence for dopaminergic modulation of reproductive behavior through D5 dopamine receptor-mediated modulation of PR-dependent behavior in rat CNS.